Cost-Effectiveness of Influenza Vaccination in Healthy Children: A 10-Year Population-Based Study.

IF 5.2 3区 医学 Q1 IMMUNOLOGY
Vaccines Pub Date : 2024-09-28 DOI:10.3390/vaccines12101113
Elisa Barbieri, Yuxi Wang, Anna Cantarutti, Antonio Scamarcia, Luigi Cantarutti, Giovanni Corrao, Aleksandra Torbica, Carlo Giaquinto
{"title":"Cost-Effectiveness of Influenza Vaccination in Healthy Children: A 10-Year Population-Based Study.","authors":"Elisa Barbieri, Yuxi Wang, Anna Cantarutti, Antonio Scamarcia, Luigi Cantarutti, Giovanni Corrao, Aleksandra Torbica, Carlo Giaquinto","doi":"10.3390/vaccines12101113","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background/Objectives</b>: Seasonal influenza annually puts a significant burden on the pediatric population, especially the youngest, causing severe illness and death. Additionally, associated healthcare costs cause a significant financial strain on healthcare systems. While vaccination is the most effective prevention method, its cost-effectiveness for healthy children remains unassessed. <b>Methods</b>: Using the Pedianet database spanning from 2009 to 2019, we analyzed influenza cases among 6-month-olds to 14-year-olds in Italy. Data included influenza-related medical visits, prescriptions, exams, emergency visits, hospitalizations, and costs. Adverse events and quality-adjusted life years (QALYs) were considered from the existing literature. A static decision-tree model compared annual vaccination strategies, assessing probabilities for influenza or influenza-like illnesses by vaccination status. Incremental cost-effectiveness ratios (ICERs) were calculated, along with sensitivity analyses and cost-effectiveness acceptability curve generation. <b>Results</b>: Mean total influenza costs for vaccinated children averaged EUR 18.6 (range 0-3175.9, including EUR 15.79 for the influenza vaccination), whereas costs for unvaccinated children were consistently lower at around EUR 4.6 (range 0-3250.1). The average ICER for years where vaccine and virus strains are matched was EUR 29,831 per QALY, which is below the EUR 40,000 threshold set by the Italian National Health Services. The ICER values range from EUR 13,736 (2017/2018) to EUR 72,153 (2013/2014). Averted influenza costs averaged EUR 23 per case, with fluctuations over the years. In most observed years, influenza vaccination was cost-effective from the healthcare providers' standpoint. The exception was 2009-2010, due to a mismatch between vaccine and virus strains. <b>Conclusions</b>: This study highlights the economic viability of influenza vaccination, especially when virus and vaccine strains align. It demonstrates the potential of vaccination programs in preserving children's health and well-being while managing healthcare costs.</p>","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":null,"pages":null},"PeriodicalIF":5.2000,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11511569/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/vaccines12101113","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background/Objectives: Seasonal influenza annually puts a significant burden on the pediatric population, especially the youngest, causing severe illness and death. Additionally, associated healthcare costs cause a significant financial strain on healthcare systems. While vaccination is the most effective prevention method, its cost-effectiveness for healthy children remains unassessed. Methods: Using the Pedianet database spanning from 2009 to 2019, we analyzed influenza cases among 6-month-olds to 14-year-olds in Italy. Data included influenza-related medical visits, prescriptions, exams, emergency visits, hospitalizations, and costs. Adverse events and quality-adjusted life years (QALYs) were considered from the existing literature. A static decision-tree model compared annual vaccination strategies, assessing probabilities for influenza or influenza-like illnesses by vaccination status. Incremental cost-effectiveness ratios (ICERs) were calculated, along with sensitivity analyses and cost-effectiveness acceptability curve generation. Results: Mean total influenza costs for vaccinated children averaged EUR 18.6 (range 0-3175.9, including EUR 15.79 for the influenza vaccination), whereas costs for unvaccinated children were consistently lower at around EUR 4.6 (range 0-3250.1). The average ICER for years where vaccine and virus strains are matched was EUR 29,831 per QALY, which is below the EUR 40,000 threshold set by the Italian National Health Services. The ICER values range from EUR 13,736 (2017/2018) to EUR 72,153 (2013/2014). Averted influenza costs averaged EUR 23 per case, with fluctuations over the years. In most observed years, influenza vaccination was cost-effective from the healthcare providers' standpoint. The exception was 2009-2010, due to a mismatch between vaccine and virus strains. Conclusions: This study highlights the economic viability of influenza vaccination, especially when virus and vaccine strains align. It demonstrates the potential of vaccination programs in preserving children's health and well-being while managing healthcare costs.

健康儿童接种流感疫苗的成本效益:一项为期 10 年的人群研究。
背景/目标:每年的季节性流感都会给儿童,尤其是最年幼的儿童带来沉重负担,导致严重的疾病和死亡。此外,相关的医疗费用也给医疗系统造成了巨大的财政压力。虽然接种疫苗是最有效的预防方法,但其对健康儿童的成本效益仍有待评估。方法:利用 2009 年至 2019 年的 Pedianet 数据库,我们分析了意大利 6 个月至 14 岁儿童的流感病例。数据包括与流感相关的就诊、处方、检查、急诊、住院和费用。根据现有文献考虑了不良事件和质量调整生命年(QALYs)。静态决策树模型比较了每年的疫苗接种策略,根据疫苗接种情况评估流感或流感样疾病的概率。计算了增量成本效益比 (ICER),同时进行了敏感性分析并生成了成本效益可接受性曲线。结果显示接种疫苗的儿童平均流感总成本为 18.6 欧元(范围为 0-3175.9,其中包括 15.79 欧元的流感疫苗接种费用),而未接种疫苗的儿童成本一直较低,约为 4.6 欧元(范围为 0-3250.1)。在疫苗和病毒株匹配的情况下,平均 ICER 为每 QALY 29,831 欧元,低于意大利国家卫生服务机构设定的 40,000 欧元阈值。ICER 值从 13,736 欧元(2017/2018 年)到 72,153 欧元(2013/2014 年)不等。避免流感的成本平均为每例 23 欧元,多年来有所波动。在大多数观察年份中,从医疗服务提供者的角度来看,流感疫苗接种都具有成本效益。但 2009-2010 年例外,原因是疫苗与病毒株不匹配。结论:本研究强调了流感疫苗接种的经济可行性,尤其是当病毒株和疫苗株一致时。它证明了疫苗接种计划在保护儿童健康和福祉的同时管理医疗成本的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Vaccines
Vaccines Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
8.90
自引率
16.70%
发文量
1853
审稿时长
18.06 days
期刊介绍: Vaccines (ISSN 2076-393X) is an international, peer-reviewed open access journal focused on laboratory and clinical vaccine research, utilization and immunization. Vaccines publishes high quality reviews, regular research papers, communications and case reports.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信